Caribou Vispa-cel Efficacy Matches Autologous CAR-T Therapy
Positive Phase 1 trial data for vispa-cel, an allogeneic (off-the-shelf) CAR-T cell therapy, demonstrates efficacy and durability comparable to traditional autologous treatments, potentially broadening access for patients with large B cell lymphoma.